Saturday 17 October 2026
Export SNWV’s income statement to Excel — free account
Sanuwave Health Inc.
SNWV Healthcare Medical Devices
Sanuwave Health Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.1 million, up 35.0% from fiscal 2024. In the quarter to June 2026, revenue fell 3.13%, EPS fell 224.2%, free cash flow grew 86.8% and total debt fell 28.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
4.96
0.21
−4.06%
Follow SNWV
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
6.02 | 9.58 | 22.70 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.95 | 3.35 | 5.80 | 7.80 | |
P/FCF ratio |
9.18 | 16.10 | 34.96 | 76.20 | |
P/Operating CF |
202.38 | 374.16 | 76.99 | 297.17 | |
P/B ratio |
30.86 | 80.82 | 157.84 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.18 | 3.57 | 6.03 | 8.14 | |
EV/EBITDA |
28.30 | 28.64 | 34.53 | 42.88 | |
EV/Operating CF |
18.35 | 27.35 | 68.51 | 258.09 | |
EV/FCF |
10.22 | 17.16 | 36.33 | 79.46 | |
Quick Ratio |
0.84 | 0.92 | 0.97 | 0.73 | |
Current Ratio |
1.28 | 1.31 | 1.38 | 1.16 | |
Net Debt/EBITDA |
78.40 | (12.97) | 5.36 | 6.40 | |
Debt/Assets |
52.39% | 55.45% | 58.81% | 65.63% | |
Debt/Equity |
6.88 | 11.19 | 13.56 | (7.97) | |
Asset Turnover |
1.26 | 1.31 | 1.31 | 1.43 | |
Operating CF/Net income |
(0.62) | (0.28) | 0.47 | 0.10 | |
Capex/Depreciation |
(1.10) | (0.43) | 0.65 | 6.55 | |
Interest Coverage |
(0.54) | (2.06) | 2.13 | 0.85 | |
Research and Development Expense of Revenue |
6.45% | 6.86% | 4.59% | 3.01% | |
Selling, General and Administrative Expense of Revenue |
70.08% | 79.52% | 56.64% | 60.18% | |
Intangible Assets out of Total Assets |
0.28 | 0.27 | 0.28 | 0.29 | |
Share Based Compensation of Revenue |
14.73% | 17.76% | 10.12% | 12.29% | |
Graham Net Nets |
(0.12) | (0.08) | (0.04) | (0.05) | |
Graham Number |
3.48 | 2.95 | 2.36 | 1.97 | |
Earnings Yield |
16.60% | 10.44% | 4.40% | (1.35%) | |
Free Cash Flow Yield |
10.89% | 6.21% | 2.86% | 1.31% | |
Revenue per Share |
1.13 | 1.12 | 1.54 | 1.34 | |
Operating CF per Share |
0.05 | 0.05 | 0.39 | 0.13 | |
Capex per Share |
(0.05) | (0.02) | 0.03 | 0.52 | |
Free Cash Flow per Share |
0.00 | 0.03 | 0.42 | 0.65 | |
Cash per Share |
1.09 | 1.25 | 1.40 | 1.12 | |
Shareholders Equity per Share |
0.32 | 0.21 | 0.19 | (0.34) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.32 | 0.21 | 0.19 | (0.34) | |
Free Cash Flow |
(0.02) | 0.24 | 3.60 | 5.56 | |
Working Capital |
5.03 | 5.65 | 6.78 | 3.06 | |
Capital Expenditures |
(0.45) | (0.16) | 0.28 | 4.48 | |
Net Current Asset Value |
(10.62) | (11.30) | (11.10) | (15.90) | |
EV/EBIT |
63.79 | 49.17 | 53.70 | 75.13 | |
Capex to Sales |
0.05 | 0.02 | (0.02) | (0.39) | |
Price to Operating Income |
57.27 | 46.13 | 51.68 | 72.04 | |
| Other line items | |||||
Average Receivables |
4.82 | 4.93 | 4.38 | 3.73 | |
Average Payables |
3.66 | 3.74 | 3.49 | 4.06 | |
Average Inventory |
6.49 | 5.68 | 5.04 | 5.12 | |
Average Assets |
34.83 | 33.98 | 33.73 | 28.72 | |
Average Common Equity |
(5.99) | (7.73) | (7.09) | (31.60) |
Columns are period end dates